



**Figure S1. Trial profile.** The schematic depicts the derivation of the LIBRETTO-001 trial population of patients with *RET* fusion-positive NSCLC and baseline intracranial metastases on which these analyses are based. The figure depicts enrollment through June 17, 2019. Patients included in this population were followed for a minimum of 6 months; the data cutoff date was Dec 16, 2019. Abbreviations: BID, twice daily; NSCLC, non-small-cell lung cancer; QD, once daily